AOD-9604: The Growth Hormone Fragment Studied for Fat Metabolism Without the Anabolic Side-Effects

AOD-9604 is a synthetic 16-amino acid fragment of human growth hormone studied for its ability to stimulate fat breakdown without the insulin-desensitising effects associated with full GH therapy. Here is what the preclinical and clinical research shows.

By UAE Peptide Clinic Research Desk

For decades, clinicians and researchers observed that supraphysiological doses of human growth hormone (hGH) could reduce adipose tissue — but at a significant cost. Elevated GH accelerates glucose intolerance, drives insulin resistance, and carries cardiovascular risks that make long-term use impractical for most patients. AOD-9604 emerged from research seeking to isolate the lipolytic signal from hGH whilst leaving the anabolic and metabolic side-effects behind. The result is a 16-amino acid peptide fragment — specifically residues 177–191 of the hGH molecule — that has attracted meaningful preclinical and clinical investigation over the past two decades.

What AOD-9604 Is and How It Works

AOD-9604 is a synthetic analogue of the C-terminal fragment of human growth hormone. Early laboratory research proposed that this specific region of the hGH molecule contained the signalling responsible for fat metabolism — distinct from the regions responsible for IGF-1 stimulation and cellular proliferation.

Preclinical studies in obese rodents demonstrated that AOD-9604 mimicked the fat-mobilising properties of native hGH — stimulating lipolysis (the breakdown of stored fat) and inhibiting lipogenesis (new fat formation) — without measurable changes in serum IGF-1 levels or fasting blood glucose. This dissociation is clinically significant: it suggests the peptide may offer metabolic benefit without the glucose dysregulation commonly associated with GH therapy.

Clinical Research: The METAOD Trials

AOD-9604 progressed into human trials, most notably the METAOD clinical programme conducted in Australia in the early 2000s. Across several randomised, placebo-controlled trials, oral AOD-9604 was assessed in overweight and obese adults over 12 weeks. Participants on higher doses demonstrated statistically significant reductions in body fat compared to placebo.

Notably, the trials reported no significant changes in blood glucose, insulin sensitivity, IGF-1, or lipid panels — consistent with the preclinical hypothesis that the lipolytic action of AOD-9604 is mechanistically separate from the growth-promoting effects of full hGH. Whilst the oral formulation did not achieve sufficient effect sizes for pharmaceutical registration in weight management, the safety and tolerability profile was favourable throughout.

AOD-9604 appears to retain the fat-mobilising signal of growth hormone whilst dissociating from the insulin-desensitising and IGF-1-stimulating properties that limit long-term GH therapy.

How AOD-9604 Is Used in Clinical Peptide Protocols

In supervised peptide therapy settings, AOD-9604 is typically administered subcutaneously, often alongside other peptides targeting body composition or metabolic health. Research suggests the peptide's lipolytic effects may be most pronounced when administered in a fasted state, as elevated insulin appears to blunt the fat-mobilising signal. For this reason, clinicians typically recommend morning administration before breakfast, or in a post-exercise window.

Important Distinctions for Patients

• AOD-9604 is not a stimulant and does not act on the central nervous system — patients should expect no thermogenic or appetite-suppressing effect.
• Its mechanism is targeted: it signals adipocytes (fat cells) to release stored fatty acids for energy, making its action metabolic rather than symptomatic.
• AOD-9604 does not stimulate the pituitary and is distinct from GH secretagogues such as CJC-1295 or Ipamorelin — it does not raise endogenous GH or IGF-1 levels.
• It is not a substitute for lifestyle intervention; research suggests it works most effectively as part of a protocol that includes appropriate nutrition and physical activity.

AOD-9604 represents one of the more thoroughly researched peptides in the metabolic space, with a clinical trial history that distinguishes it from many newer compounds. For patients seeking targeted support for body composition as part of a physician-supervised protocol, it merits consideration — particularly for those who are not candidates for GH secretagogue therapy or wish to avoid IGF-1 stimulation. If you would like to understand whether AOD-9604 is appropriate for your goals, take our personalised assessment or book a consultation with one of our physicians.